1. Home
  2. JBLU vs MESO Comparison

JBLU vs MESO Comparison

Compare JBLU & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JetBlue Airways Corporation

JBLU

JetBlue Airways Corporation

N/A

Current Price

$4.47

Market Cap

2.1B

ML Signal

N/A

Logo Mesoblast Limited

MESO

Mesoblast Limited

N/A

Current Price

$16.50

Market Cap

2.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JBLU
MESO
Founded
1998
2004
Country
United States
Australia
Employees
N/A
N/A
Industry
Air Freight/Delivery Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.1B
IPO Year
2002
2005

Fundamental Metrics

Financial Performance
Metric
JBLU
MESO
Price
$4.47
$16.50
Analyst Decision
Sell
Strong Buy
Analyst Count
13
1
Target Price
$4.91
N/A
AVG Volume (30 Days)
22.7M
182.6K
Earning Date
04-28-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
27.83
N/A
EPS
N/A
N/A
Revenue
$9,062,000,000.00
N/A
Revenue This Year
$12.11
$629.74
Revenue Next Year
$6.75
$30.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.87
$12.66
52 Week High
$6.62
$21.50

Technical Indicators

Market Signals
Indicator
JBLU
MESO
Relative Strength Index (RSI) 31.75 50.32
Support Level $3.87 $13.81
Resistance Level $5.07 $17.33
Average True Range (ATR) 0.19 0.47
MACD -0.08 -0.04
Stochastic Oscillator 1.71 37.88

Price Performance

Historical Comparison
JBLU
MESO

About JBLU JetBlue Airways Corporation

JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: